Avi Roy
@agingroy
Followers
3K
Following
5K
Media
605
Statuses
7K
Biomed Scientist in #longevity. Mentor & Investor in Health startups. Past CTO @BioVivaScience ,Researcher @CASMIORG ,Lead @oxfordscisoc @NewsInLongevity ,BGRF
Oxford, England
Joined May 2008
Peptides like BPC-157 and TB-500 are being sold with bold promises: faster healing, anti-aging, tissue repair—backed by "promising animal studies" and influencer testimonials. Here's what they don't tell you: 🚩 Zero human clinical trials. None. Not one. ✅ Compare that to
3
9
36
NEW VIDEOS from the London Healthtech Roundtable! "Funding and Deploying AI in Deeptech & Healthtech" Watch Mariam (@InterSystems), Lluna (Vector Bioscience Cambridge), Dr Avi Roy (Longevous), and Savina (Nyalt Precision) as they discuss: • Real AI applications being deployed
0
1
3
Mounjaro launched in India in March 2025. By October, it became India's #1 drug, dethroning Augmentin, the antibiotic that had held the top spot for years. 7 months. For context: Globally, Mounjaro became the world's most-prescribed drug in 3 years (fastest in pharmaceutical
Mounjaro Becomes India’s Top-Selling Drug Weight Loss Now Outweighs Everything Else https://t.co/12oMjCY0LS
0
0
3
The breakthrough: These changes are reversible. ✓ Lifestyle: 2-5 years reversed ✓ GLP-1 drugs: 3.1 years in 32 weeks ✓ Exercise: 2-4 years ✓ Weight loss: 3-5 years Your biological clock isn't destiny. 📚 Read the research: @newscientist Article: https://t.co/jgMHVqUeWb
0
0
0
Here's why: Obesity triggers the same biological pathways that define aging itself. 1️⃣ Chronic inflammation ages your inflammatory system by 5 years 2️⃣ Nutrient-sensing pathways stay "always on," preventing cellular repair 3️⃣ DNA methylation patterns shift—measurable on
1
0
0
If you were born after 1965, your body may be aging faster than any previous generation. New research on people aged 28–31 found some are biologically 45—a 50% gap between biological and chronological age. The culprits: obesity, chronic inflammation, stress. But there’s hope.
1
0
1
GPT-5 shows real progress in medicine with 65-78% fewer major errors than previous models, but Stanford researchers found it still fails on >50% of the hardest clinical scenarios. The insight: AI improvements are meaningful and medical safeguards remain essential @StanfordMed
0
1
1
This is a fantastic summary of the data. It moves the conversation from "which drug class is best?" to "which drug for which risk?" The analysis of 26 trials shows: 1️⃣ SGLT2i (Jardiance, etc.) are the clear winners for heart failure & kidney protection. 2️⃣ GLP-1 (Ozempic,
🩺 Cardiorenal outcomes in T2DM + CKD: Network Meta-Analysis (143k pts) A systematic review and network meta-analysis 📊 26 RCTs • SGLT2i ranked highest for ↓ renal events, eGFR > 40% decline, HF & MACE • GLP-1 RA ↓ MI , stroke & macroalbuminuria • Both ↓ all-cause
0
0
4
The world's governments just realized the same thing simultaneously: GLP-1s cost $5 to make. They cut heart attacks by 20%, deaths by 27%, and save healthcare systems billions. Three governments acted in 30 days. India's generics launch in 4 months. The global accessibility
0
1
2
UK researchers tracked 500,000 people for 12 years and found naproxen (Aleve) users had lower death rates—10% overall and 13% in men. Sounds promising, but the study can't prove cause and effect. It could be the drug or that healthier people use it. Observational studies are
0
0
1
Chloroplasts are organelles in plants and algae. They encode the proteins involved in photosynthesis, and so are very important. Historically, it has been very difficult to engineer a chloroplast. But a new paper out in Nature Plants seems to be a big step forward. For context:
8
60
253
This is a fascinating new analysis. It predicts that Mounjaro/Zepbound may be better at lowering the 10-year risk of a first heart attack or stroke compared to Ozempic/Wegovy. The key word is "predicted." This isn't a head-to-head trial counting actual heart attacks. Instead,
Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hocanalysis of the SURMOUNT-5 trial In SURMOUNT-5, treatment with tirzepatide was associated with greater predicted 10-year CVD risk reduction compared with semaglutide. This
0
0
2
My latest for @latimes: I travelled to southern India to document the rise of the AI "arm farms" — where young engineers strap GoPros to their foreheads and fold laundry or pack boxes to teach humanoid robots how to do chores. https://t.co/o6dgEtbuEN
132
1K
8K
A study of 130,000+ adults found long-term melatonin use (≥1 year) linked to 90% higher odds of heart failure & 3.5x higher hospitalization risk over 5 years. But this study shows correlation, not causation. This probably says more about chronic insomnia damaging your heart
2
0
5
China's biotech sector just hit a major milestone: 93 overseas licensing deals worth $85B in the first 8 months of 2025—the 6th consecutive record year. A decade ago, China's pharma industry was "copycat" generics. Today, companies like @AkesoInc, Hengrui Pharmaceuticals, and
0
0
1
Learn more about GLP-1 drugs and cancer scan accuracy: 🔬 1️⃣ Clinical case report: https://t.co/NuJ0C0HrYd - How brown fat activated by GLP-1s mimicked cancer on PET scans—important for head/neck imaging 2⃣ Patient-friendly overview @Independent: https://t.co/ATtngX0ZGH -
independent.co.uk
GLP-1 drugs may interfere with medical imaging, leading to unnecessary tests, researchers have found
0
0
0
Sources: 📊 Tirzepatide Q3 2025: $10.1B revenue (@EliLillyandCo) https://t.co/03y960hQ9I 📊 Keytruda took 9 years to #1 (@Merck reports) 📊 Clinical data: 22.5% weight loss, 94% diabetes prevention (@NEJM, @NatureMedicine SURMOUNT trials) 📊 2.5B people with obesity globally
0
0
1